Table 1.
Acute hemorrhagic edema of infancy | Henoch‐Schönlein purpura | Kawasaki disease | Sweet syndrome | |
---|---|---|---|---|
Typical age of onset | 6 mo to 2 y | 2‐6 y | 13‐24 mo | 30‐50 y |
Appearance of lesions | Annular and targetoid, erythematous and purpuric plaques | Urticarial papules progressing to palpable purpura | Nonspecific; morbilliform, urticarial, or scarlatiniform morphologies | Tender, erythematous papules and plaques |
Typical location | Face, ears, distal extremities | Lower extremities, buttocks | Diffuse | Limbs, face, neck |
Duration of individual lesions | 1‐3 wk | 5 d | Several days | 3‐9 d (with treatment) |
Duration of rash | 1‐3 wk | 4‐6 wk | Days to weeks | 3‐9 d (with treatment); recurrence common |
Mucous membrane involvement | No | No | Yes—lip and tongue erythema | Rarely |
Facial or acral edema | Yes | Yes | Yes | No |
Fever | Variable | Variable | Yes | Variable |
Associated signs/symptoms | Malaise, irritability | Malaise, arthralgias, abdominal pain | Nonexudative conjunctivitis, cervical lymphadenopathy | Malaise, myalgias, arthralgias |
Inciting factors | Infection, medications, immunizations | Infection, medications, immunizations | Infection | Infection, immunodeficiency, medications, malignancy |
Pathology | Leukocytoclastic vasculitis; direct immunofluorescence typically negative | Leukocytoclastic vasculitis; direct immunofluorescence may demonstrate IgA deposition | Vasculitis with inflammatory infiltrate of neutrophils and macrophages | Dermal edema, neutrophilic infiltrate, leukocytoclasis without vasculitis |
Type of hypersensitivity reaction | Type III | Type III | Unknown | Type IV |
Treatment | Supportive care | Organ‐directed support of renal, GI, joint manifestations | Intravenous immunoglobulin and aspirin | Systemic corticosteroids or potassium iodide |
Risk for severe complications | Low | Moderate | High | High |
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.